SK to strengthen technical ties with Chinese company

Published: 2011-10-18 06:56:00

Updated: 2011-10-18 06:56:00

SK Biopharmaceuticals Co., which was established in April as a subsidiary of the SK Group’s holdings company SK Corp., said Sunday that it has signed a licensing agreement with a Chinese drug firm to develop and market a potential treatment for depression and bipolar disorder.

Under the terms...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK